Crystal structure of SARS-CoV-2 3CL in apo form

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.

SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIRKSNHNFLVQAGNVQLRVIGH
SMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDCVSFC
YMHHMELPTGVHAGTDLEGNFYGPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYE
PLTQDHVDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQCSGVTFQ

Severe acute respiratory syndrome coronavirus 2

0.1 M sodium phosphate-monobasic, 0.1 MES, and 20% (w/v) PEG 4000

Columbia Technology Ventures and the Columbia Translational Therapeutics (TRx) program

National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)

National Science Foundation (NSF, United States)

National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)

National Institutes of Health/National Center for Research Resources (NIH/NCRR)

National Institutes of Health/Office of the Director

the crystal structure also suggests that 3CL forms dimer.

3CL Main Protease, VIRAL PROTEIN, HYDROLASE